开创了第一类FAAH-HDAC抑制剂作为潜在的多目标神经保护剂
Alessandro Papa1, Ilaria Cursaro1, Luca Pozzetti1
1Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Archiv der Pharmazie
|September 26, 2023
概括
研究人员开发了针对内分泌大麻素系统 (ECS) 和表观遗传酶的新型化合物,以防止神经退行性疾病. 化合物4h表现出显著的神经保护作用,在初步研究中表现优于标准治疗.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 氧化压力有助于神经退行性疾病.
- 同时针对内分泌大麻素系统 (ECS) 和表观遗传机制提供了一种新的治疗策略.
- 脂肪酸胺基酸酶 (FAAH) 和基因素脱乙酸酶 (HDAC) 是参与这些通路的关键酶.
研究的目的:
- 设计,合成和评估抑制FAAH和HDAC的新型多目标导向配体 (MTDLs).
- 在氧化应激模型中探索这些MTDL的神经保护潜力.
- 为未来的治疗开发确定化合物.
主要方法:
- 使用药融合策略来设计基于1-基的化合物.
- 合成化合物并评估它们对FAAH和HDAC的抑制活性.
- 在氧化应激条件下,在1321N1人类星系细胞和SHSY5人类神经元细胞中评估了神经保护作用.
主要成果:
- 成功合成了新的FAAH-HDAC抑制剂 (4a-j化合物).
- 化合物4c,4f和4h表现出强大的纳米分子抑制活性.
- 化合物4h与N-乙半氨酸相比,在体外表现出平衡的抑制和优越的神经保护,保护细胞免受氧化攻击.
结论:
- 开发的化合物代表了第一类的FAAH-HDACMTDLs.
- 化合物4h在与氧化压力相关的疾病中显示出有希望的神经保护性质.
- 这些发现为开发针对ECS和神经保护的表观遗传酶的新MTDL奠定了基础.
相关概念视频
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
147
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
147
01:26Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
01:26Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513